D. E. Shaw & Co., Inc. Cure Vac N.V. Transaction History

D. E. Shaw & Co., Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.94 - $4.34 $641,631 - $947,170	218,242 Added 78.63%	495,780 $1.5 Million
Q4 2023 Feb 14, 2024	BUY	$3.96 - $6.41 $1.1 Million - $1.78 Million	277,538 New	277,538 $1.17 Million
Q4 2022 Feb 14, 2023	BUY	$5.75 - $8.5 $350,152 - $517,616	60,896 Added 111.06%	115,726 $697,000
Q3 2022 Nov 14, 2022	SELL	$7.48 - $15.24 $213,352 - $434,690	-28,523 Reduced 34.22%	54,830 $432,000
Q2 2022 Aug 15, 2022	BUY	$13.18 - $19.41 $935,661 - $1.38 Million	70,991 Added 574.27%	83,353 $1.13 Million
Q1 2022 May 16, 2022	BUY	$14.73 - $35.25 $75,432 - $180,515	5,121 Added 70.72%	12,362 $242,000
Q4 2021 Feb 14, 2022	SELL	$33.72 - $48.22 $316,023 - $451,917	-9,372 Reduced 56.41%	7,241 $248,000
Q3 2021 Nov 15, 2021	SELL	$49.26 - $74.5 $68,766 - $104,002	-1,396 Reduced 7.75%	16,613 $907,000
Q2 2021 Aug 16, 2021	BUY	$56.91 - $127.53 $1.02 Million - $2.3 Million	18,009 New	18,009 $1.32 Million
Q1 2021 May 17, 2021	SELL	$79.79 - $126.29 $6.65 Million - $10.5 Million	-83,337 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$46.76 - $136.27 $3.9 Million - $11.4 Million	83,337 New	83,337 $6.76 Million

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $538M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.